BioMarin Pharmaceutical Inc. Stock News

In this article we will take a look at whether hedge funds think BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a good investment right now. We check hedge fund and billionaire investor sentiment befor

All the banks and brokerage firms that we follow here at 24/7 Wall St. keep a list for their institutional and retail clients of high-conviction stock picks.

SAN RAFAEL, Calif., May 19, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the initial purchasers of the previously announced offering of its 1.25% Senior Subord

We are only in May, but 2020 is already one of the most incredible years in stock market history.

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing.

BioMarin: Appeal Is On The Increase

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is beefing up its gene therapy portfolio.

BioMarin (BMRN) beats estimates for both earnings and sales in the first quarter. It lowers its total revenue outlook for the year due to the potential impact of coronavirus outbreak.

The biotech is experiencing some disruption from the COVID-19 pandemic, but not enough to derail its growing momentum.

BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q1 2020 Results - Earnings Call Transcript

BioMarin (BMRN) delivered earnings and revenue surprises of 90.91% and 6.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

In spite of Covid-19 and global recession concerns, we have a positive outlook on the biotechnology sub-industry; we expect to see a ramp-up in new drug sales; the continued development of many new, i

In what has become truly the most challenging investing environment in decades, it is probably no surprise to most investors that health care is the top-performing sector this year in the S&P 500.

Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment

Is this a prime opportunity for investors to buy the gene therapy drugmaker?